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Introduction 
Primary follicular lymphoma (FL) arising in the gastrointestinal 
tract is a rare situation. Although the gastrointestinal tract is the 
most common site for extranodal lymphomas, FL only account for 
1–3% of gastrointestinal non-Hodgkin’s lymphomas [1]. 
The gastrointestinal FL is recognized as a variant of FL in the 
2008 edition of WHO classification [2]. It shares common 
features with nodal FL in regards to morphology and 
immunophenotype, such as the expression of CD10 and BCL-6 
markers [3]. 
In an extensive literature review of 249 patients, Yamamoto et 
al. reported that the gastrointestinal FLs had a tendency of low 
histological grade (Grade 1, 84.4%; Grade 2, 11.3%; Grade 3, 
4.3%), low clinical stage of either Stage I (66.3%) or II (26.9%), 
and more favorable outcome than that of nodal FL [4]. 
The duodenum is the most frequent site for gastrointestinal FL 
[3–4]. In a retrospective study of 125 patients, Takata et al. 
reported that the most common involved site was the second 
portion of the duodenum, and it was associated with better 
progression-free survival than other FLs of the gastrointestinal 
tract [5]. 
Although recent studies have elucidated clinicopathological 
aspects of the disease, the clinical manifestations, prognosis and 
treatment have not been fully addressed. There is no consensus 
regarding the initial management. However, radiotherapy is 
considered the most powerful and effective treatment for 
localized low-grade non-Hodgkin’s lymphoma [6]. 
The purpose of this study is to report our initial experience of 
21 patients treated with primary radiation therapy and to explore 
the clinical course, prognosis and curability of the duodenal FL. 
 
Materials and Methods 
Study design 
This historical cohort study was approved ethically by the 
institutional review board (Approval No. 2015–1127) and 
scientifically by the scientific review board (Approval No. 1663) 
of the Japanese Foundation for Cancer Research. Records of 
patients with localized FL of the duodenum treated with definitive 
radiation therapy between January 2005 and December 2013 at 
the Cancer Institute Hospital of the Japanese Foundation for 
Cancer Research were reviewed. Information concerning patient 
characteristics, detailed initial treatment, acute and late toxicities, 
relapses and salvage treatment, and outcomes were collected with 
chart review. 
 
Diagnosis and staging 
A diagnostic biopsy was obtained through endoscopic exam in all 
patients before initial treatment. All biopsy specimens were fixed 
in formalin, followed by hematoxylin and eosin (H&E) staining 
and immunohistochemical staining, including CD20 and bcl-2 
markers. If the initial diagnosis was performed by an outside 
hospital or clinic, all patients were re-examined by upper 
endoscopy with biopsy at our hospital. 
Clinical staging was performed by physical examination, 
complete blood count, endoscopic examination, bone marrow 
biopsy and diagnostic imaging of CT and PET-CT scan. Staging 
was done according to the Lugano staging classification for 
primary gastrointestinal tract lymphoma. 
 
Initial treatment: radiation therapy 
All patients were treated with radiation therapy to the involved 
site. The radiation dose, using 15-MV photons, was delivered in a 
schedule of 30.6 Gy in 17 fractions for a non-bulky lesion and 
39.6 Gy in 22 fractions for a bulky lesion, respectively. The 
clinical target volume (CTV) included the whole duodenum, and 
the planning target volume (PTV) was delineated by adding a 
1-cm margin to the CTV. The 3D conformal radiation therapy was 
planned to the PTV using the three-field technique or four-field 
technique (AP–PA field plus opposed lateral or oblique field). 
Respiratory and peristaltic motions of the duodenum were 
evaluated by fluoroscopy with oral contrast media. The individual 
radiation fields were confirmed to include sufficient margin for 
the internal movement of the duodenum through the conventional 
simulator using fluoroscopy. No chemotherapy and/or antibody 
therapy was administered as an initial regimen. 
 
Follow-up and statistical analysis 
Patients were followed every 2–3 months for the first year, and 
every 6 months for the following year. Endoscopic examination 
was performed 3 months post-treatment. 
The 3-year overall survival (OS), relapse-free survival (RFS) 
and local control (LC) rates were analyzed statistically in all 
patients. Overall survival was defined as the period from the first 
day of radiotherapy until the date of death due to any cause. RFS 
was defined as the period from the first day of radiotherapy until 
the date of first documented recurrence or the date of death due to 
any cause, whichever occurred earlier. The LC rate was defined as 
the period from the first day of radiotherapy until the date of the 
first documented local relapse. All statistical analyses were 
calculated by the Kaplan–Meier method, with statistical 
difference tested by logrank test. A P value of <0.05 was 
considered to be statistically significant. All the statistical 
analyses were performed with Predictive Analytic Software 
(PASW), version 18.0 (SPSS Inc., Chicago, IL). 
 
Results 
Baseline characteristics and staging 
A total of 21 patients were retrospectively reviewed. The patient 
baseline characteristics are described in Table 1. Many of the 
patients (71%) were asymptomatic at presentation and were 
incidentally diagnosed by upper endoscopic exam. Eight patients 
(38%) had a medical history of solid tumor of the gastrointestinal 
tract (esophageal cancer, gastric cancer and colon cancer) and 
underwent routine upper endoscopic exam for either preoperative 
workups or postoperative surveillance. The other causes of initial 
endoscopy were follow-up of non-malignant diseases (peptic 
ulcer, gastroenteritis) in three patients (14%), annual health 
examination in two patients (10%), further evaluation of 
gastrointestinal bleeding in one patient (5%) and workups for 
elevated tumor marker (CA19-9) in one patient (5%). All patients 
with medical history of gastrointestinal solid cancer (38%) were 
in complete remission prior to definitive treatment of duodenal 
FL. 
 
Table 1. Patient baseline characteristics 
Characteristics Patients (n)  
Age (year)   
  Median 62 (Range 46-79)  
Gender  
  Male 6  
  Female 15  
Stage (Lugano)  
  I 20  
  II1 1 
Histological grading （WHO）  
  1 17 
  2 4 
Immunohistochemical feature 
CD20 and BCL-2 positive 21  
International Prognostic Index (IPI) Score 
  Low 21 
Follicular Lymphoma International Prognostic Index (FLIPI) Score 
  Low 19  
  Intermediate 2  
Primary site of tumor location  
  2nd portion 15 
  3rd portion 3 
  2nd and 3rd portion 2 
  2nd and 4th portion 1 
Symptom  
  Jaundice 1 
  Heartburn 1  
  Chest pain 1 
  Anemia 1  
  Abdominal discomfort  2 
  No symptom 15  
 
The clinical staging procedures of all patients are listed in Table 2. 
The PET/CT scan results are shown in Table 3. The FDG-PET/CT 
was performed in 19 patients, and only 7 cases (37%) showed 
positive results in the primary site. 
 
Table 2. Multiple modality performed in staging procedure 
  Patients (n) 
Chest CT 18  
Abdominal CT 18  
PET/CT 19  
Gallium Scan 2  
Upper endoscopy 21  
Capsular endoscopy 2  
Colonoscopy  14  
Bone marrow biopsy 21  
 Table 3. The results of the initial PET/CT study 
  Patients (n)  
PET/CT  
 primary site positive  7  
 primary site negative 12  
 
Survivals and failure patterns 
The median follow-up duration of all patients was 43.2 months 
(range, 21.4–109.3 months). The 3-year OS, RFS and LC rates 
were 94.7%, 79.3% and 100%, respectively (Fig. 1). None died of 
the disease; the death of one patient was related to acute myeloid 
leukemia, which developed 7.6 months after definitive treatment 
of FL. 
 Fig. 1. Overall survival, relapse-free survival and local control 
rate for 21 patients. 
 
No incidence of local relapse is reported at this time. There 
were four recurrences, and the failure sites are listed in Table 4. 
All of the recurrent sites were outside the treated volume. One 
recurrence was bone marrow invasion by FL cells. The patient 
died due to acute myeloid leukemia, and FL recurrence was 
diagnosed incidentally in the process of post bone marrow 
transplant evaluation. The other recurrent sites were within the 
abdominal cavity: mesenteric lymph node, terminal ileum and 
jejunum. No symptom was associated with the recurrence. The 
recurrence was diagnosed by routine endoscopic exam or PET/CT 
scan. Salvage therapy of immunochemotherapy, namely, 
rituximab, cyclophosphamide, vincristine (oncovin) and 
prednisone (R-CVP) was planned. Successful results were seen in 
three cases, where the patients completed the second line 
treatment, and all of them maintain second complete remission. In 
the analysis of recurrence, there were no differences by gender, 
clinical stage, histological grade, International Prognostic Index 
(IPI) score, Follicular Lymphoma International Prognostic Index 
(FLIPI) score or past medical history of gastrointestinal solid 
cancer [7, 8]. 
 
Table 4. Sites of first failure 
Sites Patients (n) 
Bone Marrow 1 
Mesenteric Lymph 
Node 
1 
Terminal Ileum 1 
Jejunum 1 
 
Toxicity 
The acute and late toxicities are listed in Table 5. Most of the 
acute toxicities were minor and acceptable. Many patients 
experienced anorexia of Grade 1 (95%). No acute toxicities 
greater than Grade 2 were reported. The late toxicities were also 
not significant, and limited to Grade 1. Mild anorexia was most 
frequently observed (24%) for late toxicity, and these patients 
recovered.  
 
Table 5. Acute and late toxicities 
Grade 1 2 3 4 5 
Acute toxicities      
Fatigue 4 0 0 0 0 
Anorexia 20 0 0 0 0 
Nausea 3 0 0 0 0 
Vomiting 1 0 0 0 0 
Gastritis 2 0 0 0 0 
Diarrhea 4 0 0 0 0 
      
Late toxicities      
Fatigue 2 0 0 0 0 
Anorexia 5 0 0 0 0 
 
Discussion 
FL is a common subtype of lymphoma in the USA and European 
countries, but it is observed less in Asian countries [9]. However, 
unlike nodal FL, almost 50% of the cases of gastrointestinal FL 
were reported from Japan [4]. Endoscopy has a high detection rate 
of gastrointestinal FL [5, 10, 11]. Most Japanese patients are 
covered with the national health insurance system have easy 
access to endoscopic exam for various clinical reasons or annual 
health examination [12]. The frequency of the endoscopic exam 
may have caused the demographic discrepancy between nodal FL 
and gastrointestinal FL. 
Earlier detection of gastrointestinal FL is possible by 
endoscopy. The disease has a distinguishable endoscopic 
appearance characterized by small whitish polypoid nodules up to 
2 mm in diameter, and this is described as ‘multiple polypoid 
lesions’, ‘multiple small polyps’, ‘multiple nodules’ or ‘multiple 
granules’. More detailed endoscopic images are enabled by 
high-resolution imaging, allowing identification of the 
microscopic features of enlarged villi, opaque whitish spots, and 
coiled vascular pattern within the villi [10, 11]. 
In our study, many patients were asymptomatic at presentation 
and were incidentally diagnosed by upper endoscopic exam at an 
early stage. Case reports of FL of the duodenum are rarely 
reported in the literature, and there is no information on whether 
early detection and treatment will lead to improvements in 
survival. Recent studies have suggested that the disease is a 
distinct entity, separate from nodal FL and represents a favorable 
outcome [4, 5, 13]. There is no common standard treatment 
strategy, and the initial management of this disease in 
controversial. This study represents our single institution 
experience of localized duodenal FL treated with radiation 
therapy. 
In regard to patient baseline characteristics, our study showed a 
female predominance in the population, which is similar to 
previous reports [1, 3, 14]. The most frequently involved 
anatomical site was the second portion of the duodenum. Low 
histological grade and low FLIPI score were presented. Many of 
the patients were asymptomatic. 
In our study, excellent LC was achieved with definitive 
radiation therapy. However, recurrences were observed in four 
cases, and all of them were outside the irradiated volume. Only 
one case presented bone marrow invasion. The patient was unable 
to undergo salvage therapy due to the progression of acute 
myeloid leukemia, which was related to the cause of death. The 
remaining three relapses were observed in the gastrointestinal 
tract (two) or abdominal lymph node (one). They were limited to 
the abdomen, and no involvement of adjacent organs or 
supradiaphragmatic lesions were observed. Consistent with 
previous reports [5, 13], our study showed a low rate of relapses 
outside the abdomen. 
Although duodenal FL shares common features with nodal FL 
in regards to morphology and immunophenotype, recent reports 
on pathological findings have suggested that the two types of FL 
are distinct. Yoshino et al. reported that the disease extent was 
confined to the submucosal layer in their findings about duodenal 
FL [3]. To explain the low tendency of disease dissemination 
outside the gastrointestinal tract, Bende et al. reported that the 
gastrointestinal FL expressed surface IgA and specific mucosal 
adhesion molecules, such as α4β7, which are rarely found in 
nodal FL. IgA is an immunoglobulin class that is the main 
effector of the mucosal immune system, and it is less frequently 
found in nodal FL. α4β7, a mucosal homing receptor, binds to 
ligand MAdCAM-1 which is an adhesion molecule that is 
selectively expressed on mucosal endothelium. The majority of 
nodal FL did not express α4β7 integrin. In contrast, intestinal FL 
and low-grade Mucosa-Associated Lymphoid Tissue (MALT) 
lymphomas were strongly positive [15]. Moreover, several other 
similarities between duodenal FL and low grade MALT 
lymphoma were found recently. 
Other clinicopathological findings, such as the lack of a 
follicular dendritic cell network [16, 17], deviation of 
immunoglobulin heavy chain (VH) usage [18], and patterns of 
gene expression [19] suggest that duodenal FL and low-grade 
MALT lymphoma have similar characteristics. Tari et al. also 
speculated that the gastrointestinal FL has an intermediate 
characteristic between nodal FL and low-grade MALT lymphoma 
based on his clinical findings of 28 gastrointestinal FLs [20]. In 
general, low-grade MALT lymphoma has a tendency to remain 
localized for a long period, and excellent clinical outcomes are 
achieved with local therapy such as surgery and radiation therapy. 
In our study, we consider that localized duodenal FL is also 
indolent, and that radiation therapy may be a favorable treatment 
option. 
The treatment strategy for early stage gastrointestinal FL is 
controversial. Historically, several therapeutic options such as 
surgery, chemotherapy, radiation therapy, or watchful waiting (no 
therapy) have been performed as initial management. Since the 
long-term outcome in a large population is unclear, there is no 
standardized treatment strategy for early stage gastrointestinal FL.  
In the largest case report of 63 patients with early stage 
duodenum FL, four main treatment strategies of watch and wait, 
radiation therapy, rituximab monotherapy or various 
chemotherapy treatments were applied. Of these 63 patients, 19 
underwent radical radiation therapy and have achieved 100% 
complete regression. Patients received a focal dose of 30–45.3 Gy 
via an abdominal bath of 24.5–30 Gy. Although, complete 
regression was also achieved in the remaining therapies, LC was 
superior with radiation therapy compared with other treatments 
[13]. 
In our initial treatment, we had satisfactory results for LC with 
low toxicity. All 21 patients achieved complete remission in LC, 
and acute toxicities were minor. These findings suggest that 
radiation therapy is potentially curative in localized low-grade FL 
of the duodenum. However, there are several issues regarding the 
optimal dose, the optimal target and the optimal timing for 
starting radiation therapy. 
In our study, the curative radiation dose was derived from a 
traditional treatment strategy of early stage low-grade lymphoma 
as 30–36 Gy, and we achieved excellent LC with 30.6 Gy in 17 
fractions. However, in an effort to evaluate a lower dose to 
low–grade lymphomas, the UK has conducted a randomized 
study to compare the standard dose (40–45 Gy in 20–23 fractions) 
with a lower dose (24 Gy in 12 fractions). There was no 
difference in the overall response rate, progression-free survival, 
or overall survival between the standard and lower dose [21]. 
Although, this trial included relapsed or resistant disease, 69% of 
the patients were to receive radical radiation therapy as first-line 
therapy, and these results suggest that low-grade lymphomas may 
be treated with a smaller dose. Therefore, the optimal dose to treat 
duodenal FL may be less than the traditional dose of 30 Gy. 
Regarding the target of radiation therapy, we have defined the 
duodenum as the involved site and irradiated the whole 
duodenum. However, there is no clear histological distinction 
between the duodenum and jejunum. In addition, the disease has a 
tendency to involve multiple sites in other parts of the 
gastrointestinal tracts. Takata et al. have reported that 85% of the 
duodenal FL had multiple involvements of the small intestine, 
predominantly the jejunum [5]. The gastrointestinal FL expresses 
α4β7 integrin, a mucosal homing receptor, which binds to ligand 
MAdCAM-1, which is selectively expressed on mucosal 
endothelium. The interaction of α4β7/MAdCAM-1 may explain 
the multifocal distribution of gastrointestinal FL in the intestinal 
lumen, but no further distribution beyond it. 
The initial staging of whether the disease is single or multifocal 
is important for determining the treatment strategy. If the tumor is 
multifocal, chemotherapy or antibody therapy will be considered. 
However, our staging process may have underestimated the 
distribution of the disease, because only selected patients 
underwent endoscopic evaluation of the whole intestine. Instead, 
our patients received a Positron Emission Tomography – 
Computed Tomography (PET/CT) scan to evaluate disseminated 
diseases [22, 23]. Only 7 cases (37%) showed positive results in 
the primary site through PET/CT, in our study. Therefore, we 
speculate that the sensitivity of PET/CT for gastrointestinal FL is 
low. This may be explained by the indolent nature and small 
proportion of the disease. For these reasons, PET/CT may not be 
sufficient to evaluate the disease distribution in the 
gastrointestinal tract. Therefore, the endoscopic evaluation of the 
entire intestinal tract may be necessary for appropriate clinical 
staging.  
Relapses occurred in the small intestine for two cases (terminal 
ileum and jejunum). The cause of the failures may be related to 
insufficient evaluation prior to treatment, or insufficient radiation 
volume. However, since we did not evaluate the whole intestine 
through endoscopy at initial clinical staging, the cause of the 
recurrence is uncertain. Considering the possibilities of multifocal 
disease distribution through the intestinal tract, the whole 
intestinal tract could be the target area for radiation. However, due 
to the fact that extended radiation volumes are related to an 
increase of toxicities, the limited target to the duodenum should 
be a favorable clinical target volume in practice. 
The optimal timing for initiating the treatment is uncertain, 
especially in asymptomatic patients. Kiess and Yahalom 
suggested that observation is the most sensible management 
strategy for localized gastrointestinal FL with no symptoms [24]. 
Schmatz reported that 7 out of 24 patients (29%) achieved 
complete regression in the watch and wait therapy group, and two 
patients developed nodal dissemination. The watch and wait 
group had no difference in survival or time to progression when 
compared with the definitive treatment group [12]. These results 
support the watch and wait policy that has been adopted in 
asymptomatic patients. However, transformation of duodenal FL 
to a more aggressive lymphoma was reported by Miyata-Takata et 
al. in a single case report [25]. Histological transformation is well 
known in nodal FL [26, 27], but less observed in duodenal FL. 
Since duodenal FL is a rare disease, the frequency of histological 
transformation, risk factors and time to transformation are 
unknown. Taking into account the possibility of transformation to 
a high-grade lymphoma, a definitive treatment for duodenal FL 
may be necessary, even in asymptomatic patients. However, the 
optimal timing to deliver definitive treatment needs further study. 
The duodenal FL is rare, and several important aspects of this 
lymphoma have still not been addressed. However, definitive 
radiation therapy provided excellent local control and presented 
as an effective treatment option. The limitation of this study are 
short follow-up periods, and long-term outcomes and toxicities 
are not evaluated. A long-term follow-up will be necessary to 
evaluate the efficacy of radiation therapy for duodenal FL. 
 
Conclusion 
In this study, duodenal FL was well controlled by 30.6 Gy of 
involved site radiation therapy. Several relapses were documented, 
and all of the relapses occurred outside the irradiated volume. 
Involved site radiation therapy could be an effective and safe 
treatment option for patients with localized low-grade FL arising 
from the duodenum. 
 
 
References 
1. LeBrun DP, Kamel OW, Cleary ML, et al. Follicular 
lymphomas of the gastrointestinal tract. Pathologic features in 
31 cases and bcl-2 oncogenic protein expression. Am J Pathol 
1992;140:1327–35. 
2. Jaffe ES. The 2008 WHO classification of lymphomas: 
implications for clinical practice and translational research. 
Hematology Am Soc Hematol Educ Program 2009:523–31. 
3. Yoshino T, Miyake K, Ichimura K, et al. Increased incidence 
of follicular lymphoma in the duodenum. Am J Surg Pathol 
2000;24:688–93. 
4. Yamamoto S, Nakase H, Yamashita K, et al. Gastrointestinal 
follicular lymphoma: review of the literature. J Gastroenterol 
2010;45:370–88. 
5. Takata K, Okada H, Ohmiya N, et al. Primary gastrointestinal 
follicular lymphoma involving the duodenal second portion is 
a distinct entity: a multicenter, retrospective analysis in Japan. 
Cancer Sci 2011;102:1532–6. 
6. Yahalom J. Radiotherapy of follicular lymphoma: updated 
roleand new rules. Curr Treat Options Oncol 2014;15:262–8. 
7. The International Non-Hodgkin’s Lymphoma Prognostic 
Factors Project. A predictive model for aggressive 
non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987–94. 
8. Solal-Céligny P, Pascal Roy, Philippe Colombat, et al. 
Follicular Lymphoma International Prognostic Index. Blood 
2004;104:1258–65. 
9. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology 
of the non-Hodgkin’s lymphomas: distributions of the major 
subtypes differ by geographic locations. Non-Hodgkin’s 
Lymphoma Classification Project. Ann Oncol 1998;9:717–20. 
10. Iwamuro M, Kawai Y, Takata K, et al. Primary intestinal 
follicular lymphoma: how to identify follicular lymphoma by 
routine endoscopy. World J Gastrointest Endosc 2013;5:34–8. 
11. Iwamuro M, Okuda M, Yumoto E, et al. Magnifying 
endoscopy for intestinal follicular lymphoma is helpful for 
prompt diagnosis. Gut Liver 2013;7:258–61. 
12. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric 
cancer in Asia: current evidence and practice. Lancet Oncol 
2008;9:279–87. 
13. Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary 
follicular lymphoma of the duodenum is a distinct 
mucosal/submucosal variant of follicular lymphoma: a 
retrospective study of 63 cases. J Clin Oncol 
2011;29:1445–51. 
14. Damaj G, Verkarre V, Delmer A, et al. Primary follicular 
lymphoma of the gastrointestinal tract: a study of 25 cases and 
a literature review. Ann Oncol 2003;14:623–9. 
15. Bende RJ, Smit LA, Bossenbroek JG, et al. Primary follicular 
lymphoma of the small intestine: α4β7 expression and 
immunoglobulin configuration suggest an origin from local 
antigen-experienced B cells. Am J Pathol 2003;162:105–13. 
16. Takata K, Sato Y, Nakamura N, et al. Duodenal follicular 
lymphoma lacks AID but expresses BACH2 and has memory 
B-cell characteristics. Mod Pathol 2013;26:22–31. 
17. Takata K, Sato Y, Nakamura N, et al. Duodenal and nodal 
follicular lymphomas are distinct: the former lacks 
activation-induced cytidine deaminase and follicular dendritic 
cells despite ongoing somatic hypermutations. Mod Pathol 
2009;22:940–9. 
18. Sato Y, Ichimura K, Tanaka T, et al. Duodenal follicular 
lymphomas share common characteristics with 
mucosa-associated lymphoid tissue lymphomas. J Clin Pathol 
2008;61:377–81. 
19. Takata K, Tanino M, Ennishi D, et al. Duodenal follicular 
lymphoma: comprehensive gene expression analysis with 
insights into pathogenesis. Cancer Sci 2014;105:608–15. 
20. Tari A, Asaoku H, Kunihiro M, et al. Clinical features of 
gastrointestinal follicular lymphoma: comparison with nodal 
follicular lymphoma and gastrointestinal MALT lymphoma. 
Digestion 2011;83:191–7. 
21. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy 
for local control in non-Hodgkin lymphoma: a randomised 
phase III trial. Radiother Oncol 2011;100:86–92. 
22. Wirth A, Foo M, Seymour JF, et al. Impact of [18f] 
fluorodeoxyglucose positron emission tomography on staging 
and management of early-stage follicular non-Hodgkin 
lymphoma. Int J Radiat Oncol Biol Phys 2008;71:213–9. 
23. Tari A, Asaoku H, Kunihiro M, et al. Usefulness of positron 
emission tomography in primary intestinal follicular 
lymphoma. World J Gastroenterol 2013;19:1992–6. 
24. Kiess AP, Yahalom J. Primary follicular lymphoma of the 
gastrointestinal tract: effect of stage, symptoms and treatment 
choice on outcome. Leuk Lymphoma 2013;54:177–80. 
25. Miyata-Takata T, Takata K, Sato Y, et al. A case of diffuse 
large B-cell lymphoma transformed from primary duodenal 
follicular lymphoma. Pathol Int 2014;64:527–32. 
26. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical 
implications of transformation of follicular lymphoma to 
diffuse large B-cell lymphoma. J Clin Oncol 
2007;25:2426–33. 
27. Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, 
riskfactors and outcome of histological transformation in 
follicular lymphoma. Br J Haematol 2012;157:188–96. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Radiation Research Volume 57巻・Issue 4 
First published online: March 23, 2016  公表済 
